Newsroom

SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the grand opening of the ZAP-X® Gyroscopic Radiosurgery® system at Kaohsiung Show Chwan Memorial Hospital (KSCH) in Taiwan. The ceremony marked a significant milestone in advancing access to next-generation non-invasive brain neurosurgery in the region. Featuring an innovative and visually striking treatment suite, patient treatments with the ZAP-X system are e...

BOSTON--(BUSINESS WIRE)--Inlightened, the tech-enabled insights platform that connects client companies to a vetted network of healthcare professionals, today announced that Rob Ramirez has joined the company as head of strategy. Ramirez brings 30 years of experience in pharmaceutical market research, healthcare insights, and commercial strategy, including senior leadership roles at Pfizer, Ipsos Healthcare, Schlesinger Group (now Trivoca Health), and, most recently, Manifest Health. Ramirez is...

LONDON & SYDNEY--(BUSINESS WIRE)--ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunit...

MCLEAN, Va.--(BUSINESS WIRE)--AIRO Group Holdings, Inc. (Nasdaq: AIRO) (“AIRO” or the “Company”), a global leader in advanced aerospace and defense technologies, today announced that it will host a conference call to report its financial results for the first quarter 2026 at 8:00 a.m., ET, on Thursday, May 14, 2026. Participants can join the call by dialing 1 (800)-715-9871 (US) or 1 (646)-307-1963 (international) and enter the access code 7911023. To listen to the live audio webcast and Q&...

PARIS--(BUSINESS WIRE)--Property & casualty insurers face a widening competitive divide with only 10% successfully scaling AI, while many remain in the pilot stage....

GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating pegsebrenatide (NLY01), Neuraly’s long-acting GLP1 receptor agonist, for the potential treatment of patients with multiple sclerosis (MS). Multiple sclerosis is a chronic and progressive autoimmune disease of the central nervous system (CNS) affecting more than 2.8 mil...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 04.05.2026 CHPS.LN IE000KXTLDE2 725,002.00 USD 31,487,761.71 43.431  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 04.05.2026 MISL.LN IE000NVDQXE1 4,150,002.00 USD 139,160,597.06 33.533  ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the EL...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline data fro...